On July 2nd, Astellas Pharma announced that the Drug Evaluation Center of the China National Medical Products Administration has approved the indication of Enzalutamide (XTANDI, Ankertan) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Previously, the approved indications for this product in China included asymptomatic or mildly symptomatic adult patients with castration-resistant prostate cancer (CRPC) who failed androgen deprivation therapy (ADT) and did not receive chemotherapy, and adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of developing metastasis. Currently, Enzalutamide has become the only novel endocrine therapy that covers each stage of advanced prostate cancer.
国家药监局批准恩扎卢胺用于治疗转移性激素敏感性前列腺癌的新适应症
The State Administration for Market Regulation has approved the new indication of Enzalutamide for the treatment of metastatic hormone-sensitive prostate cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.